175 related articles for article (PubMed ID: 24218050)
1. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.
Hurvitz SA; Lalla D; Crosby RD; Mathias SD
Breast Cancer Res Treat; 2013 Dec; 142(3):603-9. PubMed ID: 24218050
[TBL] [Abstract][Full Text] [Related]
2. Progression-free survival and quality of life in metastatic breast cancer: The patient perspective.
Mertz S; Benjamin C; Girvalaki C; Cardone A; Gono P; May SG; Comerford E; Than KS; Birch K; Roach M; Myers S; Sasane M; Lavi L; Cameron A; Cardoso F
Breast; 2022 Oct; 65():84-90. PubMed ID: 35870420
[TBL] [Abstract][Full Text] [Related]
3. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.
Müller V; Nabieva N; Häberle L; Taran FA; Hartkopf AD; Volz B; Overkamp F; Brandl AL; Kolberg HC; Hadji P; Tesch H; Ettl J; Lux MP; Lüftner D; Belleville E; Fasching PA; Janni W; Beckmann MW; Wimberger P; Hielscher C; Fehm TN; Brucker SY; Wallwiener D; Schneeweiss A; Wallwiener M
Breast; 2018 Feb; 37():154-160. PubMed ID: 29237546
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States.
Zanotti G; Hunger M; Perkins JJ; Horblyuk R; Martin M
BMC Cancer; 2017 Jun; 17(1):393. PubMed ID: 28578656
[TBL] [Abstract][Full Text] [Related]
5. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
6. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy.
Pimentel I; Lohmann AE; Ennis M; Dowling RJO; Cescon D; Elser C; Potvin KR; Haq R; Hamm C; Chang MC; Stambolic V; Goodwin PJ
Breast; 2019 Dec; 48():17-23. PubMed ID: 31472446
[TBL] [Abstract][Full Text] [Related]
7. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
8. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
Petrelli F; Barni S
Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
[TBL] [Abstract][Full Text] [Related]
9. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose.
Schneeweiss A; Hensel M; Sinn P; Khbeis T; Haas R; Bastert G; Ho AD
Ann Oncol; 2002 May; 13(5):679-88. PubMed ID: 12075735
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
[TBL] [Abstract][Full Text] [Related]
11. Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment.
Robinson AG; O'Donnell J; Booth C; Koven R; Eisenhauer E; Brundage M
J Cancer Policy; 2021 Dec; 30():100301. PubMed ID: 35559797
[TBL] [Abstract][Full Text] [Related]
12. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
Vrdoljak E; Marschner N; Zielinski C; Gligorov J; Cortes J; Puglisi F; Aapro M; Fallowfield L; Fontana A; Inbar M; Kahan Z; Welt A; Lévy C; Brain E; Pivot X; Putzu C; González Martín A; de Ducla S; Easton V; von Minckwitz G
Ann Oncol; 2016 Nov; 27(11):2046-2052. PubMed ID: 27502725
[TBL] [Abstract][Full Text] [Related]
13. Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis.
Tjokrowidjaja A; Lee CK; Houssami N; Lord S
Intern Med J; 2014 Aug; 44(8):764-70. PubMed ID: 24863750
[TBL] [Abstract][Full Text] [Related]
14. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
16. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
19. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
20. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
